Imunon, Inc. Debt Securities, Available-for-sale, Realized Gain (Loss)
Imunon, Inc. (IMNN) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $61.98 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2025-02-27
- Imunon, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Imunon, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Imunon, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-06-30 was $135.45K.
- Imunon, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-03-31 was -$73.47K.
- Imunon, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2024 was $61.98K, a 85.65% decline from fiscal 2023.
- Imunon, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2023 was $431.80K.
- Imunon, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2022 was -$49.22K.
- Imunon, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2021 was -$7.15K, a 113.40% decline from fiscal 2020.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month as first filed | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $135.45K derived: sum of 3 quarters · filed 2025-02-27 | $61.98K 10-K · filed 2025-02-27 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $135.45K derived: sum of 2 quarters · filed 2024-11-07 | $61.98K 10-Q · filed 2024-11-07 | $466.87K derived: sum of 4 quarters · filed 2025-02-27 | |
| 2024-06-30 | $135.45K 10-Q · filed 2024-08-14 | $61.98K 10-Q · filed 2024-08-14 | $466.87K derived: sum of 3 quarters · filed 2025-02-27 | $630.04K derived: sum of 4 quarters · filed 2025-02-27 | |
| 2024-03-31 | -$73.47K 10-Q · filed 2024-05-13 | $331.42K derived: sum of 2 quarters · filed 2025-02-27 | $494.59K derived: sum of 3 quarters · filed 2025-02-27 | $461.42K derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-12-31 | $404.89K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $568.06K derived: sum of 2 quarters · filed 2025-02-27 | $534.89K derived: sum of 3 quarters · filed 2025-02-27 | $431.80K 10-K · filed 2025-02-27 | |
| 2023-09-30 | $163.17K 10-Q · filed 2024-11-07 | $130.00K derived: sum of 2 quarters · filed 2024-11-07 | $26.91K 10-Q · filed 2024-11-07 | $11.99K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$33.17K 10-Q · filed 2024-08-14 | -$136.26K 10-Q · filed 2024-08-14 | -$151.18K derived: sum of 3 quarters · filed 2024-08-14 | -$161.54K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$103.08K 10-Q · filed 2024-05-13 | $103.08K 10-Q · filed 2023-05-11 | -$118.00K derived: sum of 2 quarters · filed 2024-05-13 | -$128.37K derived: sum of 3 quarters · filed 2024-05-13 | -$149.97K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$14.92K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$25.29K derived: sum of 2 quarters · filed 2024-03-28 | -$46.88K derived: sum of 3 quarters · filed 2024-03-28 | -$49.22K 10-K · filed 2024-03-28 | |
| 2022-09-30 | -$10.37K 10-Q · filed 2023-11-14 | -$31.96K derived: sum of 2 quarters · filed 2023-11-14 | -$34.30K 10-Q · filed 2023-11-14 | -$36.93K derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | -$21.60K 10-Q · filed 2023-08-10 | -$23.93K 10-Q · filed 2023-08-10 | -$26.56K derived: sum of 3 quarters · filed 2023-08-10 | -$29.30K derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$2.34K 10-Q · filed 2023-05-11 | -$4.97K derived: sum of 2 quarters · filed 2023-05-11 | -$7.70K derived: sum of 3 quarters · filed 2023-05-11 | -$9.49K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$2.63K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$5.36K derived: sum of 2 quarters · filed 2023-03-30 | -$7.15K derived: sum of 3 quarters · filed 2023-03-30 | -$7.15K 10-K · filed 2023-03-30 | |
| 2021-09-30 | -$2.74K 10-Q · filed 2022-11-14 | -$4.52K derived: sum of 2 quarters · filed 2022-11-14 | -$4.52K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | -$1.78K 10-Q · filed 2022-08-15 | -$1.78K 10-Q · filed 2022-08-15 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $7.26K derived: sum of 2 quarters · filed 2022-03-31 | $53.35K 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $7.26K 10-Q · filed 2021-11-15 | $53.35K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |